Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

Go to United States (English)
skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Sector Verification

This section contains information intended for healthcare professionals.

Please confirm that you are affiliated with a healthcare organization.

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

Published: 13/11/2026 | Modified: 13/11/2026

Sebia has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.

These are the first EIA tests receiving 510(k) from the FDA for the quantitative detection of both kappa and lambda free light chains (FLC) in human serum specimens, intended for both aid of diagnosis and monitoring of #Multiple Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.

As a global leader for multiple myeloma testing, Sebia expands its offer in the U.S. with this new solution, easily adaptable to automated immunoassay instruments for a high throughput processing. The ELISA format overcomes main challenges in analytical performance often seen in alternative testing methods
Arnaud Collin Sebia Group Vice President Global Regulatory Affairs & Quality

Test associated with this resource